2-Furan-2-yl-7-(2-methoxy-phenyl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Furan-2-yl-7-(2-methoxy-phenyl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine
• 英文别名: 2-(furan-2-yl)-7-(2-methoxyphenyl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-amine
• 化学式: C₁₆H₁₃N₅O₂
• 分子量: 307.312
• InChiKey: BLFOGUJARWOELP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  91.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-呋喃甲酰肼 在 四(三苯基膦)钯 、 N,O-双三甲硅基乙酰胺 、 potassium carbonate 作用下， 以 乙腈 、 正丁醇 为溶剂， 生成 2-Furan-2-yl-7-(2-methoxy-phenyl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine
  参考文献：
  名称：

  2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1

  摘要：

  The structure-activity relationship of this novel class of compounds based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, 1, and its analogs was evaluated for their in vitro and in vivo adenosine A(2A) receptor antagonism. Several compounds displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound 8g displayed an excellent in vitro profile, as well as a highly promising in vivo profile. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.086

文献信息

• 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1
  作者：Julius J. Matasi、John P. Caldwell、Hongtao Zhang、Ahmad Fawzi、Mary E. Cohen-Williams、Geoffrey B. Varty、Deen B. Tulshian

  DOI：10.1016/j.bmcl.2005.05.086

  日期：2005.8

  The structure-activity relationship of this novel class of compounds based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, 1, and its analogs was evaluated for their in vitro and in vivo adenosine A(2A) receptor antagonism. Several compounds displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound 8g displayed an excellent in vitro profile, as well as a highly promising in vivo profile. (c) 2005 Elsevier Ltd. All rights reserved.